Oxford–AstraZeneca COVID-19 vaccine efficacy

Maria Deloria Knoll; Chizoba Wonodi

doi:10.1016/S0140-6736(20)32623-4

Oxford–AstraZeneca COVID-19 vaccine efficacy

Maria Deloria Knoll, Chizoba Wonodi

Bloomberg School of Public Health

Research output: Contribution to journal › Comment/debate › peer-review

53 Scopus citations

Original language	English (US)
Pages (from-to)	72-74
Number of pages	3
Journal	The Lancet
Volume	397
Issue number	10269
DOIs	https://doi.org/10.1016/S0140-6736(20)32623-4
State	Published - Jan 9 2021

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(20)32623-4

Cite this

@article{b1e1fa7bf9414a04bf1e36c3f0ec92cf,

title = "Oxford–AstraZeneca COVID-19 vaccine efficacy",

author = "Knoll, {Maria Deloria} and Chizoba Wonodi",

note = "Funding Information: MDK reports grants and personal fees from Merck and grants from Pfizer, outside of the area of work commented on here, and is a subgrant recipient on an unrelated study conducted by the principal investigator of this trial. CW has received grant funding and personal fees from Merck, outside of the area of work commented on here.",

year = "2021",

month = jan,

day = "9",

doi = "10.1016/S0140-6736(20)32623-4",

language = "English (US)",

volume = "397",

pages = "72--74",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10269",

}

TY - JOUR

T1 - Oxford–AstraZeneca COVID-19 vaccine efficacy

AU - Knoll, Maria Deloria

AU - Wonodi, Chizoba

N1 - Funding Information: MDK reports grants and personal fees from Merck and grants from Pfizer, outside of the area of work commented on here, and is a subgrant recipient on an unrelated study conducted by the principal investigator of this trial. CW has received grant funding and personal fees from Merck, outside of the area of work commented on here.

PY - 2021/1/9

Y1 - 2021/1/9

UR - http://www.scopus.com/inward/record.url?scp=85097473982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097473982&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(20)32623-4

DO - 10.1016/S0140-6736(20)32623-4

M3 - Comment/debate

C2 - 33306990

AN - SCOPUS:85097473982

SN - 0140-6736

VL - 397

SP - 72

EP - 74

JO - The Lancet

JF - The Lancet

IS - 10269

ER -

Oxford–AstraZeneca COVID-19 vaccine efficacy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this